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Bone qualityThe aim of this work was to study the effects of cyclosporine (CsA), tacrolimus (FK-506), and rapamycin (RAPA)
on bone mass, femoral microstructure, femoral biomechanical properties, and bone remodeling in healthy adult
male rats.
Forty-eight 5-month-old male Wistar rats were used. CsA (2 mg/kg/day), FK-506 (3 mg/kg/day), RAPA
(1.25 mg/kg/day), or water (0.5 ml/rat/day, control group) were administered orally for 3 months.
After sacriﬁce, mean values of immunosuppressants in blood were: CsA (670.4 ng/ml), FK-506 (19.2 ng/ml), and
RAPA (4.8 ng/ml). Levels of biochemical parameters were normal in all groups. Femoral BMD was decreased in
FK-506 and RAPA groups and lumbar BMD in FK-506 group. Trabecular volume fraction (BV/TV) decreased
only in FK-506 group. RAPA and CsA affected femoral cortical structure, but FK-506 did not. FK-506 produced
an increase in bone remodeling, and CsA a decrease. FK-506 group showed a decrease in biomechanical param-
eters relative to all groups. RAPA group showed a decrease in ultimate stress vs control group, and CsA group pre-
sented an increase in biomechanical parameters versus control group.
We found that administration of both RAPA and FK-506 as monotherapy for healthy rats produced osteopenia.
CsA treatment only produces slight damages in the cortical zone of the femur.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
With the use of new and more powerful immunosuppressive drugs,
survival rates in patients receiving solid-organ transplantation have im-
proved signiﬁcantly due to effective control of acute rejection episodes.
However, a substantial number of works describe the development of os-
teoporosis among patients who have received transplantation of organs
such as the kidney, heart, or liver (Monegal et al., 2001; Al-Gabri et al.,
2005; Maalouf and Shane, 2005; Kulak et al., 2012; Wang et al., 2013;
Monegal et al., 2013). These patients have increased risk of vertebral
and nonvertebral fracture (Ramsey-Goldman et al., 1999). The rate of
bone loss increases during the ﬁrst year after kidney or heart transplanta-
tion but experiences a stabilization at the lumbar level. However, in parts
of the skeletonwhere cortical bone is predominant, like the hip, an accel-
erated rhythm of bone loss is maintained over the years following trans-
plantation (Delmas, 2001). Osteoporosis and increased risk of fracture
have a negative impact on the quality of life of patients. In view of the. This is an open access article undermorbidity and mortality associated with hip and vertebral fractures,
such a pattern will inﬂuence the quality of life of these patients.
The many factors contributing to the pathogenesis of osteoporosis
after transplantation include the underlying disease (e.g., primary bili-
ary cirrhosis), concurrent disorders, hypogonadism, postoperative mal-
nutrition and immobilization, and treatment with glucorticoids. The
negative effects of glucocorticoids on bone are known (Delmas, 2001).
In recent years, however, the accepted dose of glucocorticoids after
transplantation has been signiﬁcantly reduced, and the action of immu-
nosuppressants themselves on bone cannot be overlooked as a potential
negative factor. Cyclosporin (CsA), FK-506 (tacrolimus), or rapamycin
(RAPA) are immunosuppressants used inmany transplantation patients.
In experimental models, CsA has been shown to induce bone loss
through an increase in bone resorption (Tsuruoka et al., 2005). Indeed,
a correlation has been observed between CsA serum concentrations
and increased bone remodeling in patients with heart (Thiébaud et al.,
1996) or liver (Giannini et al., 2000) transplantation.While it is currently
accepted that FK-506 presents minor secondary effects when compared
to CsA, there are also works that show that this immunosuppressant in-
creases bone remodeling and brings about a signiﬁcant decrease in bonethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and in experimental models (Kirino et al., 2004). RAPA, on the other
hand, is a more novel treatment. According to several reports, its effects
on bone are lower than those of other immunosuppressants (Romero
et al., 1995; Campistol et al., 2005). In spite of the importance of the
problem, there are few works in the literature that study the causes of
bone loss in patients who have undergone solid-organ transplantation.
The importance of this question led us to study the actions of 3 com-
monly used immunosuppressants on bone quality: CsA, FK-506, and
RAPA. Due to the difﬁculty of performing this study in humans as a re-
sult of heterogeneity in age, transplanted organ, sex, and initial patient
status, we decided to usemale adult rats as a homogenous experimental
model. Rats have been previously used by many investigators to study
bone loss and the positive and negative effects of various drugs on loss
of bone (Zhu, 2010).
The aim of this work was: 1) to establish an experimental model of
administration of immunosuppressants to healthy male rats in which
the level of blood immunosuppressants was similar to the levels clini-
cally accepted for human patients treated with these drugs; and 2) to
use this experimentalmodel to comparatively study the effects produced
by CsA, FK-506, and RAPA on BMD, trabecular and cortical bone micro-
structure, biomechanical properties, and bone remodeling through the
levels of biochemical markers of bone turnover.
2. Materials and methods
2.1. Animals
Forty-eight ﬁve-month-old male Wistar rats weighing 405 ± 32 g
(mean ± SD) were used. The animals were kept under constant living
conditions (22 °C, 12 h per day of light–dark cycles), and food (standard
laboratory chow) and water were available ad libitum.
The animals were randomized to 4 different groups: SHAM (n= 12),
in which each rat received 300 μl/day of distilled water by oral gavage;
CsA (n=12), in which each rat received 2mg/kg/day of CsA by oral ga-
vage; RAPA, in which each rat received 1.25 mg/kg/day of RAPA by oral
gavage; FK-506, in which each rat received 3 mg/kg/day of FK-506 by
oral gavage. Treatment was maintained for 3 months.
2.2. Immunosuppressant preparation
Doses of immunosuppressantswere prepared according to amedium
weight of the experimental rats of 400 g. Cyclosporine A (Sandimmun,
100mg, Novartis) was diluted in distilled water (150 µl of CsA in 5475
µl of distilled water). 300 µl of this dilution was administered daily by
oral gavage to each rat (2 mg/kg/day). FK-506 (Tacrolimus, Prograf
5mg, capsules). Each day, the content of 4 capsules (20mg) was diluted
in 2 ml of ethanol to solubilize the product and 3 ml of distilled water
were added. 300 µl of this dilution was administered daily by oral
gavage to each rat (3 mg/kg/ day). Rapamicine (Rapamune, 1 mg/ml,
oral solution, Wyeth) was administered directly to rats from pharma-
ceutical preparation, 500 µl/rat by oral gavage daily (1.25 mg/kg/day).
Each rat of the SHAM group received daily 300 µl of distilled water by
oral gavage.
The day following the last treatment, the experimental animalswere
weighed and sacriﬁced by exsanguinationwhile under ether anesthesia.
Blood samples were obtained by cardiac puncture (2 ml with EDTA for
determination of immunosuppressant levels in total blood) and 7 ml
without any additive for serum determinations. Total blood was imme-
diately used to determine immunosuppressant levels, and serum
aliquots were frozen at −80 °C until determination of biochemical
markers of bone turnover or other biochemical determinations. Once
the blood was collected, the animals were frozen at−20 °C until deter-
mination of BMD in previously thawed animals. Prior to BMD analyses,
the left femurs were excised and cleaned of adjacent tissue. The right
femur was also excised and cleaned for computerizedmicrotomographicanalysis (μCT) and biomechanical testing. Lumbar spine BMD was de-
termined in situ. Repeated freeze–thaw cycles have been shown to
have no inﬂuence on the mechanical properties of bone (Borchers
et al., 1995). All the experiments with animals were carried out accord-
ing to Spanish law regarding the use, protection, and care of experimen-
tal animals (Royal Decree 53/2013).
2.3. Blood immunosuppressants
2.3.1. CsA
The automated Dimension® CSA method uses an immunoassay
technique in which free and CsA-bound antibody-enzyme species are
separated using magnetic particles. CsA was measured in whole blood
samples (EDTA tubes) thatwere previouslymixed and lysed. Sensitivity
of the methods was 25 ng/ml and inter- and intra-assay variation coef-
ﬁcients were b11% and b15.9%, respectively.
2.3.2. FK-506
FK-506 levelsweremeasured in an IMx analyzer (Abbott, Germany),
which performs microparticle enzyme analysis (MEIA). FK-506 was
measured in whole blood samples (EDTA tubes) previously extract-
ed using a precipitation reagent. The sensitivity of the method was
4.1 ng/ml and inter- and intra-assay variation coefﬁcients were b4%
and b10%, respectively.
2.3.3. RAPA
RAPA levels were measured in an IMx analyzer (Abbott, Germany).
This autoanalyzer also performs MEIA. RAPA was measured in whole
blood samples (EDTA tubes) previously extracted using a precipitation
reagent. The sensitivity of the method was 1 ng/ml and inter- and
intra-assay variation coefﬁcients were b7% and b9%, respectively.
2.4. BMD
BMDwas determined in situ in the lumbar spine (L2, L3, and L4) and
in the whole left femur by dual energy X-ray densitometry (DEXA)
using a HOLOGIC QDR-1000 TM (S/N 277) (Hologic, Inc., Waltham,
MA, USA) with small-animal software (Gala Paniagua et al., 1998).
Intra-assay and inter-assay variation coefﬁcients were b0.53% and
b1.2%, respectively. The femur scans were analyzed for BMD of the
whole femur. The scans of the L2, L3, and L4 vertebrae were analyzed
for BMD of the whole 3 vertebrae and the results were expressed as
the mean of the values obtained.
2.5. Trabecular and corticalmicroarchitecture analysis of femur bymicroCT
The distal region of the right femur was analyzed by μCT (Skyscan
N.V., Aartselaar, Belgium) imaged with an X-ray tube voltage of
100 kV and a current of 100 μA, and with a 1.0 mm aluminum ﬁlter.
The trabecular and cortical bone femur region were studied. For
more details, see reference De La Piedra et al. (2011).
2.6. Biomechanical testing
The femora were subjected to mechanical testing with a Microtest
EM1/10/FR/m testing machine (Microtest, S.A., Madrid, Spain) and
3-point bending strength was measured. The extrinsic biomechanical
properties of bone include ultimate force, stiffness, and work to failure.
The intrinsic biomechanical properties include ultimate stress, apparent
young modulus, and toughness. For more details, see reference De La
Piedra et al. (2011).
2.7. Biochemical markers of bone turnover
Serum bone Gla protein (Osteocalcin) (BGP) was determined by
ELISA for the speciﬁc quantitative determinationof rat osteocalcin levels
Table 1
Blood levels of immunosuppressants.
Time after administration Immunosuppressant dose
CsA
2 mg/kg/day
FK-506
0.10 mg/kg/day
RAPA
0.05 mg/kg/day
2 h 550 ± 47 ng/ml Undetectable Undetectable
24 h 200 ± 23 ng/ml Undetectable Undetectable
Time after administration Immunosuppressant dose
CsA
2 mg/kg/day
FK-506
3 mg/kg/day
RAPA
1.25 mg/kg/day
2 h 670 ± 50 ng/ml 19 ± 2 ng/ml 10 ± 1.5 ng/ml
24 h 153 ± 20 ng/ml 4 ± 0.6 ng/ml 4 ± 1.4 ng/ml
Blood levels of immunosuppressants after the daily administration of the indicated doses
of cyclosporine (CsA), tacrolimus (FK-506) and rapamycin (RAPA) during 3 months to
ﬁve-month-old male Wistar rats (n = 3 rats/group).
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50 ng/ml. The intra- and inter-assay coefﬁcients of variation of the
method were b5.0% and b6.6%, respectively.
Serum aminoterminal propeptide of collagen I (PINP) was assayed
by a speciﬁc serum ELISA for rat PINP (Rat/Mouse PINP EIA, IDS, UK).
Assay sensitivity was 0.7 ng/ml. The intra- and inter-assay variation co-
efﬁcients of the method were b5.0% and b8.2%, respectively.
Serum 5b isoenzyme of tartrate-resistant acid phosphatase
(TRAP) was measured by an ELISA speciﬁc for rat TRAP (RatTRAP
Assay, IDS, UK). The sensitivity of the assay was 0.1 U/L. Intra- and
inter-assay variation coefﬁcients of the method were b5.0% and
b5.5%, respectively.
Serum C-telopeptide of type I collagen (CTX) was measured by an
ELISA speciﬁc for rat CTX (RatLaps ELISA, IDS, UK). The sensitivity ofFig. 1. Biochemical markers of bone turnover in ﬁve-month-old male Wistar rats treated w
0.05 mg/kg/day) over three months. Statistical signiﬁcance: Mann–Whitney test; a: signiﬁcant
FK-506 vs. control p b 0.05; RAPA vs. control p b 0.05. BGP: CsA vs. control p b 0.05, FK-506
p b 0.001. CTX/TRAP: FK-506 vs. control p b 0.01, FK-506 vs. CsA p b 0.01, RAPA vs. FK-506 p bthe assay was 2.0 ng/ml. Intra- and inter-assay variation coefﬁcients of
the method were b5.6% and b10.5%, respectively.2.8. 25(OH) vitamin D analysis
The 25(OH) vitamin D was determined in rat serum by ELISA (25-
hydroxyvitamin D EIA, IDS, UK). The sensitivity of the assay was
2 ng/ml. Intra- and inter-assay variation coefﬁcients of the method
were b5.6% and b6.4%, respectively.2.9. PTH analysis
Serum PTH was determined in rat serum by ELISA (Rat Bioactive
Intact PTH ELISA kit, Immutopics, USA). This technique is a third-
generation PTH assay in which only (1–84) molecule (intact PTH) are
measured. The sensitivity of the assay was 3 pg/ml. Intra- and inter-
assay variation coefﬁcients of the method were b3.9% and b8%,
respectively.2.10. Other biochemical determinations
Calcium, creatinine, gamma-glutamyl-transpeptidase (gamma-GTP),
and alkaline phosphatase (AP) in rat serum were determined in a
VITROS 5.1 autoanalyzer of the integrated system VITROS 5600 (Ortho
Clinical Diagnostics). Sensitivity and intra- and inter-assay variation coef-
ﬁcients of the methods were, respectively: calcium 1.4 mg/dl, b1.5% and
b1.9%; creatinine 0.05mg/dl, b1% and b2.5%; gamma-GTP 10 UI/L, b1.2%
and b1.6%; and AP 20 IU/L, b1.5% and b1.9%.ith cyclosporine (CsA, 2 mg/kg/day), FK-506 (0.1 mg/kg/da), and rapamycin (RAPA,
vs. control; b: signiﬁcant vs. CsA; c: signiﬁcant vs. FK-506. PINP: CsA vs. control p b 0.01;
vs. control p b 0.001, FK-506 vs. CsA p b 0.001, RAPA vs. CsA p b 0.01, RAPA vs. FK-506
0.05.
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The results of the experiments were expressed as the mean± SD of
the different parameters. A non-parametric method, the Mann–
Whitney test (Medcalc Software Program, Belgium), was used to com-
pare the different treatment groups. P-values b0.05 were accepted as
denoting a signiﬁcant difference.
3. Results
3.1. Experimental model: blood levels of immunosuppressants
Administration of immunosuppressants to rats over 3months at a
dose that is similar to the dose/kg ratio used in humans produced un-
detectable blood levels of FK-506 and RAPA, though also producing
acceptable levels of CsA (Table 1). We administered increasing
amounts of FK-506 and RAPA until we reached acceptable blood
levels of immunosuppressants (data not shown). Deﬁnitive doses
of immunosuppressants are shown in the lower part of Table 1:
2 mg/kg/day of CsA, 3 mg/kg/day of FK-506, and 1.25 mg/kg/day of
RAPA, and this was the experimental model used in the present
work.
3.2. Bone remodeling markers
Fig. 1 shows the serum levels of the biochemical markers of bone
formation PINP and BGP and the biochemical index of bone resorp-
tion CTX/TRAP following administration of CsA, FK-506, and RAPA
to the rats over 3 months according to the doses indicated in the
Materials and methods section above. Levels of PINP decreasedFig. 2. Femoral and lumbar BMD in ﬁve-month-old male Wistar rats treated with
cyclosporine (CsA, 2 mg/kg/day), FK-506 (0.1 mg/kg/day) and rapamycin (RAPA,
0.05 mg/kg/day) during three months. Statistical signiﬁcance: Mann–Whitney test; a:
signiﬁcant vs, control; b: signiﬁcant vs. CsA; c: signiﬁcant vs. FK-506. Femoral BMD:
FK-506 vs. control p b 0.001, FK-506 vs CsA p b 0.001, RAPA vs. control p b 0.05, RAPA vs.
FK-506 p b 0.01. Lumbar BMD: FK-506 vs. control p b 0.001, FK-506 vs. CsA p b 0.001,
RAPA vs. FK-506 p b 0.01.signiﬁcantly in the 3 groups of treated animals with respect to the
untreated group, and no signiﬁcant differences were detected between
the treatment groups. BGP levels decreased signiﬁcantly in the group
treated with CsAwith respect to the control group and increased signif-
icantly in the group treated with FK-506. The group treated with RAPA
did not show signiﬁcant differences with respect to the untreated
group. Levels of CTX/TRAP were signiﬁcantly increased with respect to
untreated rats only in the FK-506 treated group, with no differences
found in the CsA and RAPA groups.3.3. Bone mineral density
Fig. 2 shows femoral (F) and lumbar (L) BMD in the rats treatedwith
immunosuppressants. FK-506 and RAPA produced a signiﬁcant de-
crease in FBMD with respect to the control group, and the decrease in
the FK-506 group was higher than in the RAPA group. CsA treatment
did not produce any signiﬁcant change in FBMD. LBMD decreased sig-
niﬁcantly only in the group treated with FK-506.3.4. Bone microstructure
3.4.1. Femoral trabecular microstructure
Fig. 3 shows the percentage of volume of bone tissue with respect to
total bone volume (BV/TV), trabecular thickness (Tb.Th), trabecular
separation (Tb.Sp), and trabecular number (Tb.N) in the femur of the
different groups of rats treated for 3 months with CsA, FK-506, and
RAPA. Only the group treated with FK-506 experienced a signiﬁcant
decrease in BV/TV and Tb.N and an increase in Tb.Sp with respect to
the control group. Neither CsA nor RAPA produced changes in femoral
trabecular microstructure.3.4.2. Femoral cortical microstructure
Table 2 shows themicrostructural parameters of the cortical bone
of rat femora treated with CsA, FK-506, and RAPA. A detrimental ef-
fect of RAPA was found in the structure of the femoral cortical
bone, with decreases in cortical area (−9.75%, p b 0.05) and rota-
tional inertia moment (−39.3%, p b 0.002). CsA also affected femoral
cortical structure, decreasing cortical area (−7.1%, p b 0.05), and
rotational IM (−14.5%, p b 0.05). FK-506 did not affect femoral cor-
tical structure. Fig. 4 shows 4 representative images of the 3D
microtomographic sections, both of trabecular and cortical zones of
the femur of the rats of the 4 studied groups. A decrease in the trabecu-
lar zonewas observed in the section that corresponds to FK-506 treated
rats, as well as a slight decrease in the cortical zone in the group treated
with RAPA.3.5. Biochemical parameters
Treatmentwith CsA, FK-506, or RAPA did not produce any alteration
in the levels of serum calcium, creatinine, gamma-GTP, AP, 25(OH) vita-
min D, or bio-PTH compared to the untreated group.3.6. Biomechanical properties of the femur
Table 3 shows the results of the bending test carried out in the femur
of the rats. The group of rats treated with FK-506 showed a signiﬁcant
decrease in ultimate load, ultimate displacement, and work to failure
with respect to all the studied groups and a decrease in ultimate strain
and toughness versus the rats treated with CsA and RAPA, with no
changes observed in ultimate stress. The RAPA group showed a decrease
in ultimate stress with respect to the control group, and the CsA group
presented an increase in ultimate displacement, work to failure, and
ultimate strain versus the control group.
Fig. 3. Percent of bone volumewith respect to total bone volume (BV/TV), trabecular thickness (Tb.Th), trabecular separation (Tb.Sp), and number of trabeculae (Tb.N) in ﬁve-month-old
maleWistar rats treatedwith cyclosporine (CsA, 2mg/kg/day), FK-506 (0.1mg/kg/da), and rapamycin (RAPA, 0.05mg/kg/day) over threemonths. Statistical signiﬁcance:Mann–Whitney
test; a: signiﬁcant vs, control; BV/TV: control vs FK-506: p b 0.05 (2). Tb.Sp: control vs FK-506: p b 0.01. Tb.N: control vs FK-506: p b 0.01.
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Table 4 shows the levels of serum calcium, creatinine, gamma-GTP,
AP, 25(OH) vitamin D, and bio-PTH in the 4 groups of rats studied.
Treatment with CsA, FK-506, or RAPA did not produce any alteration
in the levels of these parameters with respect to the untreated group.
4. Discussion
One of the main problems when studying the action of immunosup-
pressants in humans is the lack of homogeneity of the population in
terms of age, transplanted organ, and patient status; homogeneity is re-
quired to performdeﬁnitive statistical studies. The use of an experimental
model eliminates these difﬁculties. For this reason, the ﬁrst objective of
ourworkwas to design an experimentalmodelwith conditions as similar
as possible to those of patients. Thus,we tried to have similar serum levels
of CsA, FK-506, and RAPA to those admitted as valid in patients treated
with these drugs. Doing this ensured that the effects of immunosuppres-
sants on bone cells of animals would be similar to the effect produced by
immunosuppressants on human bone cells.We started administering the
same concentrations of immunosuppressants per kg of body weight that
usually were administered to humans; however, with the exception ofTable 2
Microstructural parameters of the cortical bone of rat femora treated with CsA, FK-506, and RA
SHAM
Cortical area, mm2 6.81 ± 0.41
Rotational inertia moment, mm4 35.3 ± 3.3
Cortical thickness, mm 0.290 ± 0.041
Microstructural parameters of the cortical of femur of ﬁve-month-old male Wistar rats tr
(RAPA, 0.05 mg/kg/day) during three months. Statistical signiﬁcance: Mann–Whitney test
of rotational inertia moment RAPA vs SHAM p b 0.01.CsA, we observed undetectable levels of immunosuppressants in blood.
By increasing the dose of administered immunosuppressants,we reached
levels of CsA (2mg/kg/), FK-506 (3mg/kg), and RAPA (1.25 mg/kg) that,
when administered daily, produced the desired levels of immunosup-
pressants in the blood of the rats.
Another important problem in the study of the effects of immuno-
suppressants in humans is the fact that patients usually take several
drugs simultaneously, therefore making it difﬁcult to isolate the effects
of each one. For this reason, we have administered only one immuno-
suppressant to each group of rats so as to study their effects separately.
It is important to note that many experimental works on the effects
of immunosuppressants on rat bone do not measure serum levels of
immunosuppressants, and in many cases the administered dose is
very high.
When we analyzed the changes in bone remodeling markers after
the treatment with immunosuppressants, only FK-506 produced a
signiﬁcant increase in BGP (marker of bone formation and bone remod-
eling) and the rate CTX/TRAP5b, showing a signiﬁcant increase in bone
remodeling after the administration of this immunosuppressant. The
fact that an increase of PINP was not observed does not rule out a
transient increase in this marker and a return to normal levels after
3 months of treatment. So, high levels of PINP were described duringPA.
CsA FK-506 RAPA
6.33 ± 0.23a 6.33 ± 0.55 6.10 ± 0.50a
30.2 ± 3.9a 30.7 ± 6.3 28.4 ± 3.8a
0.313 ± 0.023 0.325 ± 0.030 0.300 ± 0.037
eated with cyclosporine (CsA, 2 mg/kg/day), FK-506 (0.1 mg/kg/da) and rapamycin
; a vs. SHAM. In all the cases the statistical signiﬁcance was p b 0.05 with the exception
Fig. 4. Representative images of the 3D microstructure sections, both of trabecular and cortical zones of the femur of ﬁve-month-old male Wistar rats treated with cyclosporine (CsA,
2 mg/kg/day), FK-506 (0.1 mg/kg/da) and rapamycin (RAPA, 0.05 mg/kg/day) during three months. a: Control, b: cyclosporine, c: tacrolimus and d: rapamycin.
79M. Rubert et al. / Bone Reports 2 (2015) 74–81the 2 ﬁrst months after ovariectomy in rats, and returned to basal levels
after 8 weeks (Rissanen et al., 2008). Treatment with CsA or RAPA did
not seem to produce a state of high remodeling unless it was transient,
and we found that a decrease in bone remodeling was produced by CsA
if we take into account values of PINP and BGP.
It is difﬁcult to make a comparison between our results and those of
other authors, because in many cases they use different doses of immu-
nosuppressants, different ages of rats, and different times of exposure to
the drugs.
With CsA doses of 1 or 5mg/kg 3 times/week for 4months (our dose
is intermediate 2 mg/kg/day), Erben et al. (2003) found an increase in
BGP in 9-month-old male Fisher rats, which contrasts with our results,
since we did not detect changes in this bone marker. In the same
work, this author found a transient increase in the resorption bone
marker urinary deoxypyridinoline (Dpyr)with CsA treatment, although
the levels for this marker seemed to return to normality after 4 months
of treatment, which mirrors our ﬁndings about CTX/TRAP5b. Our ﬁnd-
ing of a general increase of bone remodeling after the treatment with
FK-506 agrees with that of Kirino et al. (2004), who found a signiﬁcant
increase of BGP and Dpyr in 8-week-old Sprague–Dawley rats that were
treated for 5 weeks with 1 mg/kg/day of FK-506 administered intraper-
itoneally. According to these authors, this dose would be equivalent to
3.2 mg/kg orally, which is the dose we employed in the present work.
Spolidorio et al. (2007) found an increase in the resorption markerTable 3
Results of the bending test carried out in the femur of the rats treated with CsA, FK-506 and RA
SHAM
Extrinsic properties (structural)
Ultimate load, N Fult 186 ± 14
Ultimate displacement, mm δult 0.69 ± 0.14
Work to failure, mJ U 75 ± 20
Intrinsic properties (material)
Ultimate stress, MPa σult 164 ± 19
Ultimate strain ult 0.06 ± 0.01
Toughness, MPa u 6.3 ± 1.6
Results of the bending test applied to the femurofﬁve-month-oldmaleWistar rats treatedwith cyc
during three months. Statistical signiﬁcance: Mann–Whitney test; p b 0.05; a vs. SHAM, b vs. cyclFATR following administration of CsA (a ﬁnding we did not reach
with the CTX/TRAP marker) in rats treated with 10 mg/kg/day of CsA
(a dose 5 times higher than ours). Another important point is that
these authors used 50 g rats, many of which were younger than ours,
a fact which could have caused the different effects of immunosuppres-
sants on bone remodeling. However, with these same animals, these au-
thors did not ﬁnd changes in the levels of FATR after the administration
of FK-506 (1 mg/kg/day versus 3 mg/kg/day in our work).
With respect to BMD, our results show that CsA did not affect levels
of lumbar or femoral BMD. Although a slight decrease in cortical area
and IM (cortical microstructure) was observed, the trabecular micro-
structure was normal and femoral microstructure was not affected. In
the case of RAPA administration, lumbar BMD was not affected, but
femoral BMD was decreased. This is due to the fact that trabecular mi-
crostructure was not affected, although there was a larger decrease
than in the case of CsA administration in the cortical microstructure
(cortical area and IM). However, FK-506 administration produced a
serious alteration in trabecular microstructure (less BV/TV and Tb.Th)
and a greater Tb.Sp. This fact produces a signiﬁcant decrease in femoral
and lumbar BMD although cortical microstructure is not affected.
There is a great controversy in the literature about the effects pro-
duced by CsA on bone mass. Erben et al. (2003) found deleterious and
transient effects on bone mass when administering 15 mg/kg/day of
CsA to male rats and also observed positive effects on female rats.PA.
CsA FK-506 RAPA
178 ± 10 158 ± 15a,b,c 172 ± 16
0.79 ± 0.07a 0.61 ± 0.14b,c 0.77 ± 0.06
90 ± 17a 61 ± 15a,b,c 83 ± 13
156 ± 25 155 ± 12 150 ± 10a
0.08 ± 0.01a 0.05 ± 0.01b,c 0.07 ± 0.01
7.5 ± 1.5 5.4 ± 1.2b,c 6.8 ± 0.9
losporine (CsA, 2mg/kg/day), FK-506 (0.1mg/kg/da) and rapamycin (RAPA, 0.05mg/kg/day)
osporine, c vs. RAPA.
Table 4
Biochemical parameters in the serum rats treated with CsA, FK-506 and RAPA.
Creatinine
mg/dl
Calcium
mg/dl
GGTP
IU/l
ALP
IU/l
25(OH)vitD
ng/ml
PTH
pg/ml
SHAM 0.610 ± 0.054 9.567 ± 0.242 1.167 ± 0.408 144.83 ± 23.28 26.0 ± 4.3 60.3 ± 36.7
CsA 0.63 ± 0.073 9.300 ± 0.253 1.000 ± 0.000 145.33 ± 26.77 29.3 ± 7.2 66.9 ± 26.8
FK-506 0.652 ± 0.050 9.767 ± 0.294 1.000 ± 0.000 160.33 ± 54.55 22.2 ± 3.8 88.2 ± 57.2
RAPA 0.608 ± 0.031 9.533 ± 0.197 1.000 ± 0.000 159.67 ± 25.60 27.3 ± 4.4 63.8 ± 34.1
Biochemical parameters in the serum of ﬁve-month-oldmaleWistar rats treated with cyclosporine (CsA, 2 mg/kg/day), FK-506 (0.1 mg/kg/day), and rapamycin (RAPA, 0.05mg/kg/day)
over three months. Statistical signiﬁcance: Mann–Whitney test. No signiﬁcant statistical differences between groups were observed.
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Sprague–Dawley rats over 28 days, found a decrease in trabecular vol-
ume. Romero et al. (1995) administered 15 mg/kg/day of CsA to
Sprague–Dawley rats that were 10 weeks old and found a 66% decrease
in trabecular area. Similar results were found by Kawana et al. (1996)
and Katz et al. (1994). The difference between the results of these au-
thors and ours could be due to their elevated dose of CsA compared
with ours (15 mg/kg/day vs. 2 mg/kg/day). However, Abdelhadi et al.
(2002), who administered our same dose to growing rats, did not ﬁnd
variations in the trabecular volume of tibial metaphysis, but they
did ﬁnd a decrease when administering 30 mg/kg/day. Nassar et al.
(2013) observed an imbalance of the alveolar bone homeostasia in
a model of experimental periodontitis after the administration of
10 mg/kg of CsA over 30 days. All the studies that show undesirable
effects on the bone of rats by CsA use high doses of CsA that could be
considered toxic. In our study, blood levels in the rats were similar to
those of treated patients and in conditions in which bone damage is
undetectable. In an interesting work, Jäger et al. (2012) demonstrated
that CsA blood levels of b200 ng/ml did not induce high turnover
osteopenia in aged rats, while higher levels induced bone loss. This con-
troversy on the effects of CsA on bone has also been observed in human
studies. Works carried out in heart-transplanted patients (Thiébaud
et al., 1996; Shane et al., 1993) show a deleterious effect of CsA on
bone mass, while other studies with monotherapy of CsA in kidney
transplant do not show bone-mass loss.
More works agree with our results reviewing the effects pro-
duced administering FK-506 to rats. Kirino et al. (2004) adminis-
tered 1 mg/kg/day of FK-506 intraperitoneally for 5 weeks and, like in
our work, recorded a decrease in trabecular volume. Fukunaga et al.
(2004), who administered intramuscularly 1 mg/kg/day of FK-506 to
rats, also observed a decrease in the femoral trabecular area. An interest-
ing ﬁnding in the work of these authors is that they did not ﬁnd any dif-
ference in the cortical bone of the rats treated with FK-506; this result is
in agreement with ours. Cvetkovic et al. (1994) also found a decrease in
trabecular volume in rats administered 5 mg/kg/day of FK-506. A de-
crease of 56% in trabecular area was also observed by Romero et al.
(1995) when the same dose of FK-506 was administered. Administering
the same dose as in our work (3 mg/kg/day of FK-506) to growing rats,
Abdelhadi et al. (2002) found a decrease in tibial metaphysis and
the same results were observed with 1 mg/kg/day administered over
5 weeks in Sprague–Dawley rats. Kosugi et al. (2013), using a morpho-
metric analysis, found that FK-506 produced osteoporosis in the femur
and mandibular condyle in Sprague–Dawley rats treated for 5 weeks.
However, results of other authors contrast with ours. Inoue et al.
(2000), who administered 10 mg/kg/day of CsA or 1 mg/kg/day of FK-
506 to male rats over 10 weeks, found a decrease in femoral BMD
with both treatments, although this decrease was more pronounced
with CsA. The difference from our results could be due to the high
dose administered. Folwarczna et al. (2009) administering a low dose
of FK-506 (0.3 mg/kg/day) to adult male rats, found that this dose in-
creased bone formation. Results that differed from ours were found by
Spolidorio et al. (2007). These authors administered 10 mg/kg/day of
CsA subcutaneously to one group of rats and 1 mg/kg/day of FK-506
to another group. After this, the group treated with CsA was treatedwith FK-506. Surprisingly, FK-506 reverted bone loss, increasing bone
volume.
There are fewer works about RAPA. One of the factors thatmay have
inﬂuence its scant clinical use and the low number of experimental
works are the difﬁcultly to determine RAPA levels by HPLC until 2006.
From this date, an automatic commercial method similar to that of
FK-506 was developed, thereby making it possible to use this com-
pound. The results of Joffe et al. (1993) agree with ours. A dose of
2.5 mg/kg/day of RAPA for 14 days did not affect trabecular volume.
Similarly, Romero et al. (1995) and Joffe et al. (1993) demonstrated
that RAPA administration did not produce changes in trabecular
volume.
All the parameters analyzed about bone quality lead to a higher or
lower bone resistance that really is the more important parameter,
responsible of the possible fracture. As we can observe in our results
on thebiomechanical properties of the femur in rats treatedwith immu-
nosuppressants, treatment with FK-506 produced the most negative
effects, especially in the extrinsic properties (ultimate load and work
to failure). Regarding intrinsic properties, although there is no signiﬁ-
cant difference between the group treated with this immunosuppres-
sant and the control group, their values are signiﬁcantly lower than
those of groups treated with CsA and RAPA. Surprisingly, CsA treatment
produced a variation in extrinsic parameters (ultimate displacement
and work to failure) and in the intrinsic (ultimate strain) in the sense
that the bone of rats treated with CsA is even more resistant than the
bone of the control group.
As for the general biochemical parameters of rats, we did not ﬁnd
signiﬁcant differences in the levels of serum calcium, gamma-GTP, cre-
atinine, or total AP. This fact indicates that immunosuppressants at
these doses did not produce renal or hepatic damage. We did not ﬁnd
any change in PTH levels after 3 months of treatment. Other authors,
such as Kirino et al. (2004), found a transient increase in PTH levels in
rats treated with FK-506 after 3 weeks of treatment, later returning to
normal levels. Cvetkovic et al. (1994) did not ﬁnd changes in calcium
or PTH after CsA treatment administered to rats, but they found changes
after 28 days of FK-506 treatment. In works with patients, some authors
demonstrated that immunosuppressants produced bone loss through a
secondary hyperparathyroidism, although other authors did not ob-
serve the same (Rubin and Bilezikian, 2002).We did not observe any al-
teration in the levels of 25(OH) vitaminD after the administration of the
3 immunosuppressants.
In conclusion, in our in vivo experiments we found that both RAPA
and FK-506 administered as monotherapy to normal rats produce
osteopenia. RAPA only affects cortical bone structure, while losses in
bone mass due to FK-506 are deeper and affect cortical and trabecular
zones. CsA treatment only produces slight damages in the cortical
zone of the femur, and bones of animals treated with this drug are
even more resistant to ﬂexion than those of control rats. Findings on
the biomechanical parameters of resistance to ﬂexion in this work cor-
related with ﬁndings in BMD and bone microstructural parameters in
the rats treated with CsA, FK-506, and RAPA. On the other hand, the in-
crease in bone remodeling found after the administration of FK-506
could explain the decrease found in bone mass, while with CsA a de-
crease in bone remodeling is observed.
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